Why Amgen Inc. (AMGN) stock moved
Amgen Inc. (AMGN) shares fell 0.6% to $364.17 as of July 21, 2026, a slight decline from the prior close of $366.29. BestStocks flagged the session as a major change for AMGN. No single company-specific catalyst was confirmed, so the move reads as a sector-wide move. Below, we break down what changed for AMGN, why it matters for investors, how the stock reacted, and the catalysts on the calendar.
AMGN fell 0.6% to $364.17
AMGN fell 0.6% in its latest session, moving from $366.29 to $364.17.
What it means for Amgen Inc. investors
For Amgen Inc. investors, the recent signals are mixed, leaving the near-term picture neutral / mixed. On the constructive side: Amgen Inc. (AMGN) moved +3.70% from $358.32 to $371.58 on 2026-07-16; A federal judge blocked Colorado's attempt to implement a price cap on Amgen's Enbrel, the company's blockbuster arthritis drug. Weighing against that: Negative session, down 0.6%; New SEC filing — review for material disclosures. Because peers moved similarly, the shift looks more macro- or sector-driven than a change in AMGN's fundamentals. Wall Street's consensus price target sits at $355.40, implying -2.4% downside from $364.17. BestStocks rates the overall signal quality weak (0/100). With earnings roughly 14 days out, the next report is the most likely near-term test of the move.
AMGN price reaction
AMGN last traded at $364.17, down $2.12 (-0.58%) from the previous close of $366.29. The session traded on 0.6× average volume (below avg), so participation was unremarkable. Its healthcare peer group moved a median -1.2% over the same stretch, leaving AMGN ahead of the group by 0.6 points. Over the past month the stock has ranged between $344.72 and $374.15, and it currently sits about 66% of the way up that band.
Bullish and bearish analyst opinions on Amgen Inc. (AMGN)
The consensus analyst price target on Amgen Inc. (AMGN) is $355.40, 2.4% below the recent $364.17. Over the past 90 days analysts logged 0 upgrades, 10 maintains, and 0 downgrades. Here is how the bullish and bearish cases on AMGN line up.
The bullish case
- The Street's most bullish target is $427.00 (+17.3%).
- Amgen Inc. (AMGN) moved +3.70% from $358.32 to $371.58 on 2026-07-16.
- A federal judge blocked Colorado's attempt to implement a price cap on Amgen's Enbrel, the company's blockbuster arthritis drug.
The bearish case
- The consensus analyst price target of $355.40 sits 2.4% below the recent $364.17, so the average target sees limited room to run.
- The most bearish analyst target is $185.00 (-49.2%).
- Negative session, down 0.6%.
Weighing both sides, BestStocks' composite read of recent signals is roughly balanced, as the bull-versus-bear meter above shows. This is an educational summary of the bull and bear case, not investment advice.
Analyst price targets and ratings are FMP consensus figures as of Jul 21, 2026; other aggregators may differ. High and low targets show the range of estimates, not forecasts.
Previous notable changes for AMGN
Frequently asked questions about AMGN
Why did Amgen Inc. (AMGN) stock move?
AMGN fell 0.6% to $364.17. No single company-specific catalyst was confirmed during the move window, and it looks like a sector-wide move.
How much did AMGN stock fall?
AMGN lost 0.58% ($2.12) versus the prior close of $366.29, last trading at $364.17 on 0.6× average volume.
When is Amgen Inc.'s next earnings date?
AMGN's next earnings report is estimated for 2026-08-04 — about 14 days away.
What is the analyst price target for AMGN?
The consensus analyst price target for AMGN is $355.40, about 2.4% below the current $364.17. Over the past 90 days, analysts recorded 0 upgrades, 10 maintains, and 0 downgrades.
Is the AMGN move company-specific or sector-wide?
BestStocks classifies it as a sector-wide move: the peer group moved a median -1.2% against AMGN's -0.6%. AMGN ranks top 2 of 7 peers.
How BestStocks tracks AMGN
This page is generated automatically by BestStocks' change-detection system after its price and volume cleared AMGN-specific materiality thresholds, triggering an evidence check. It draws on 10 tracked change events for AMGN, cross-checked against the data sources listed below. Price, volume, and market-capitalization figures are the live intraday quote as of July 21, 2026 and refresh as new information is detected; for companies with multiple share classes, market-cap figures can differ by data source. Analyst price targets and ratings are FMP consensus. This is an educational summary of what changed and why — not personalized investment advice.